# A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Study · id `cardio:ct-nct01043029` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01043029](<https://clinicaltrials.gov/study/NCT01043029>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01043029

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.

## Technical summary

Registry record NCT01043029. Randomized; double masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 302 participants (enrolled count; ClinicalTrials.gov record NCT01043029, source copy `cardio:ctgov-nct01043029-2016-11-02`, retrieved 2026-10-26)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01043029, source copy `cardio:ctgov-nct01043029-2016-11-02`, retrieved 2026-10-26)
- Primary completion: 2012-07 (actual) (ClinicalTrials.gov record NCT01043029, source copy `cardio:ctgov-nct01043029-2016-11-02`, retrieved 2026-10-26)
- Completion: 2012-07 (actual) (ClinicalTrials.gov record NCT01043029, source copy `cardio:ctgov-nct01043029-2016-11-02`, retrieved 2026-10-26)
- Countries: Australia; Brazil; Colombia; El Salvador; Germany; Hong Kong SAR China; Hungary; Italy; Mexico; Peru; Romania; Russia; Slovakia (ClinicalTrials.gov record NCT01043029, source copy `cardio:ctgov-nct01043029-2016-11-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01043029-2016-11-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
- Condition: Diabetes Mellitus Type 2
- Intervention (Drug): aleglitazar
- Intervention (Drug): pioglitazone
- Lead sponsor: Hoffmann-La Roche
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study (`cardio:pubmed-25407798`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 449b5c436be46a9c6d4763322cb7dd2a04e74832bdff15abe2c1d0fe2ae49dbc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
